Unicycive Therapeutics, Inc. cotiza a 3.73 USD y tiene una capitalización bursátil de $104M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients w…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.06 | $-0.82 | $-0.33 |
| Estimado | $-0.35 | $-0.33 | $-0.46 | $-0.53 |
| Sorpresa | — | +81.8% | -78.3% | +37.7% |
| Métrica | UNCY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -87.9% | -40.4% | -47.5% |
| ROA | -54.0% | -32.0% | -22.0% |
| Current Ratio | 2.59 | 2.84 | -0.25 |
| Debt / Equity | — | 0.28 | — |